NEW YORK (GenomeWeb News) – Intradigm Corporation has licensed rights to a nucleic acid delivery patent from the Massachusetts Institute of Technology for use in RNAi drug development.
The Palo Alto-based company said the IP it has licensed covers a broad range of biodegradable polymer structures that are used in delivering RNAi-based therapeutics. It added that the license would enable it to pursue applications for its NanoPlex technology across a broader range of therapeutic indications.
Intradigm’s RNAi Nanoplex technology is made of an active siRNA molecule and a biodegradable polycationic polymer.
The company said it will use the licensed technology to “identify, develop, and commercialize optimal delivery platforms.”
Financial terms of the agreement were not released.